Stockscreener 앱 받기
17.80
4.09%
0.70
전일 마감가:
$17.10
열려 있는:
$17.13
하루 거래량:
2.34M
Relative Volume:
0.79
시가총액:
$4.25B
수익:
$426.45M
순이익/손실:
$197.67M
주가수익비율:
21.71
EPS:
0.82
순현금흐름:
$110.10M
1주 성능:
+4.77%
1개월 성능:
+4.40%
6개월 성능:
+12.37%
1년 성능:
+1.71%
1일 변동 폭
$16.99
$17.84
1주일 범위
$16.85
$17.89
52주 변동 폭
$14.62
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
명칭
Adma Biologics Inc
전화
(201) 478-5552
주소
C/O ADMA BIOLOGICS, INC., RAMSEY
ADMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
17.80 | 4.21B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-19 | 재개 | Raymond James | Strong Buy |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2021-11-11 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-04 | 개시 | Jefferies | Buy |
| 2019-04-15 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-07 | 재개 | H.C. Wainwright | Buy |
| 2017-12-11 | 재확인 | Maxim Group | Buy |
| 2017-11-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | 업그레이드 | Maxim Group | Hold → Buy |
| 2016-08-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2016-07-25 | 재확인 | Maxim Group | Buy |
| 2015-05-13 | 재확인 | Maxim Group | Buy |
| 2014-12-08 | 개시 | Oppenheimer | Outperform |
| 2014-12-01 | 재확인 | Maxim Group | Buy |
모두보기
Adma Biologics Inc 주식(ADMA)의 최신 뉴스
Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
New Strong Buy Stocks for October 7th - MSN
Live Scanner Shows Breakout on ADMA Biologics Inc.2025 Pullback Review & Target Return Focused Stock Picks - kangso.co.kr
ADMA Biologics Shares Surge Amid Market Optimism - TipRanks
ADMA Biologics Inc. Added to Custom Quant Screener TodayForecast Cut & Fast Exit Strategy with Risk Control - metrotimes.co.kr
Adma Biologics CEO Adam Grossman sells $354k in shares By Investing.com - Investing.com Canada
Adma Biologics CEO Adam Grossman sells $354k in shares - Investing.com
Published on: 2025-08-15 19:06:15 - thegnnews.com
ADMA Biologics (NASDAQ:ADMA) Is Posting Healthy Earnings, But It Is Not All Good News - 富途牛牛
Why ADMA Biologics Inc. stock attracts strong analyst attentionFree Double Return Watchlist - thegnnews.com
ADMA projects $1.1B revenue before 2030 as yield enhancement drives margin expansion and ASCENIV growth - MSN
How did ADMA's revenue surge in Q4 2024 impact its profitability? - AInvest
ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform - Seeking Alpha
Is ADMA Biologics Inc. forming a double bottomHigh Octane Equity Watchlist - newsyoung.net
Insider Sellers Might Regret Selling ADMA Biologics Shares at a Lower Price Than Current Market Value - 富途牛牛
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum - MSN
ADMA Biologics Thrives With Blockbuster Growth And New FDA Edge - Finimize
ADMA Biologics Earnings Call Highlights Robust Growth - The Globe and Mail
ADMA Biologics' Stock Underperforms After Q1 Results - AInvest
ADMA Biologics: A Better Quarter Than Headline Numbers (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics 2025 Q2 Earnings Strong Performance as Net Income Rises 6.7% - AInvest
ADMA Biologics Secures $300M Credit Agreement with JPMorgan - AInvest
ADMA Biologics Rides ASCENIV Demand To Higher Guidance - Finimize
ADMA Biologics Outpaces Expectations With Upbeat Growth Plans - Finimize
Noteworthy Thursday Option Activity: ADMA, SMMT, ICHR - Nasdaq
ADMA Biologics Sees Promising Gains Amid Strategic Shifts and Rising Market Trends - timothysykes.com
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
ADMA Beats On Q2 Earnings And Revenues, Asceniv Drives Momentum - Barchart.com
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations - Investing.com
ADMA Biologics Inc earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
Adma Biologics (ADMA) Q2 Revenue Up 14% - AOL.com
ADMA Biologics Reports Strong Q2 2025 Results - TipRanks
ADMA Biologics Q2 2025 Earnings Call Transcript - MarketBeat
ADMA Biologics (ADMA) Projects Significant Growth with Yield Process and Refinancing - GuruFocus
ADMA Biologics: A Tale of Two Narratives—Strong Fundamentals vs. a Pessimistic Rating - AInvest
ADMA Biologics' Q2 2025: Unraveling Contradictions in Yield Enhancements, Reimbursement, and Demand Dynamics - AInvest
ADMA Biologics Q2 2025 Earnings Call Transcript Review - AInvest
ADMA Biologics' Q2 2025 Earnings and Strategic Outlook: Navigating Insider Sales and Risk Disclosures for Long-Term Value - AInvest
Adma Biologics Inc (ADMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Adma Biologics Inc 주식 (ADMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Aug 15 '25 |
Sale |
16.88 |
21,000 |
354,480 |
2,031,850 |
| Kestenberg-Messina Kaitlin M. | COO and SVP, Compliance |
Jul 30 '25 |
Option Exercise |
8.98 |
2,500 |
22,450 |
489,898 |
| Grossman Adam S | President and CEO |
Jul 15 '25 |
Option Exercise |
5.40 |
15,000 |
81,000 |
2,058,850 |
| Grossman Adam S | President and CEO |
Jul 15 '25 |
Sale |
18.66 |
21,000 |
391,860 |
2,037,850 |
0.94%
1.72%
자본화:
|
볼륨(24시간):